Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2008

View Archived Issues

Canakinumab demonstrates clinical benefit in patients with Muckle-Wells syndrome / News in Context

PF-03814735 doses, tolerability explored in solid tumor patients

MethylGene commences phase II MGCD-0103 trial in combination with Vidaza

Mpex initiates phase II aerosol MP-376 trial for chronic bacterial infections in CF

MediGene reports positive results from phase IIa clinical trial of RhuDex in RA

NITD and TB Alliance enter 5-year research collaboration for TB medicines

FDA approves 150 mg strength of Warner Chilcott's Doryx delayed-release tablets for acne

Melior and Pfizer sign option agreement for MLR-1023 for type 2 diabetes

European Commission approves extension of Amgen's marketing authorization for Mimpara

Bivalent cholera vaccine shows immunogenicity and protection against Vibrio cholerae infection

Pierre Fabre reports phase I results for omtriptolide in acute leukemias

Kinesin spindle protein inhibitor AZD-4877 evaluated in phase I studies at AstraZeneca

Astellas Pharma launches Lexiscan as pharmacologic stress agent in radionuclide MPI

Preclinical safety studies of MT-203 in inflammatory and autoimmune diseases begin

PAION completes acquisition of CeNeS

Protherics initiates enrollment in phase IIa study of angiotensin therapeutic vaccine

GPC Biotech initiates phase II trial of satraplatin in combination with prednisone in HRPC

FDA approves Sirion's NDA for Durezol in postoperative ocular inflammation and pain

New agents for treatment of HCV infection described in recent Tibotec and Arrow patents

Alkermes initiates phase III Vivitrol study for opioid dependence

Recent patents describe novel analgesic agents

Ardea reports additional positive phase IIa results for RDEA-806 in HIV

Phase III data show tasimelteon significantly improves sleep in insomnia

Avalon nominates lead clinical development candidate AVN-316

Recent Pharmacopeia patent discloses new JAK3 inhibitors

New data reported for Qnexa in high cardiovascular risk type 2 diabetics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...